Journal of the American Society of Nephrology, Vol 7, 325-330, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients

J Kletzmayr, H Kotzmann, T Popow-Kraupp, J Kovarik and R Klauser
Department of Nephrology and Dialysis, University of Vienna, Austria.

Recent studies showed contradictory results concerning the efficacy of oral acyclovir in the prevention or amelioration of cytomegalovirus (CMV) disease after renal transplantation (TX). This study evaluated the incidence and severity of CMV disease within the first year after TX in high-risk renal transplant recipients (CMV-seropositive donor, seronegative recipient) treated prophylactically with oral acyclovir (800 to 3200 mg/day) over a period of 12 wk (ACY, N = 22), compared with high-risk patients randomly assigned as controls (CO, N = 10). Follow-up for CMV infection included serological determination of CMV- specific immunoglobulin G and immunoglobulin M antibodies, antigen detection in peripheral blood leukocytes (PP 65), shell vial culture (blood), and virus isolation/early antigen detection (urine). Severity of CMV disease was quantified by a scoring system for CMV-related symptoms. Nine patients (40.1%) in the acyclovir group and four patients (40%) in the control group developed CMV disease. Neither severity (ACY, 11.4 versus CO; 12.5 points score), nor duration of disease (ACY, 21 days; CO, 22 days), nor transplant function at the end of the observation period differed significantly. The onst of CMV disease was not delayed significantly in acyclovir-treated patients compared with controls (ACY, 47 +/- 34 days versus CO, 27 +/- 14 days after TX, not significant). Our results show no beneficial effect of oral acyclovir prophylaxis in CMV high-risk renal transplant recipients.

This article has been cited by other articles:

				A. C. Kalil, J. Levitsky, E. Lyden, J. Stoner, and A. G. Freifeld Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Ann Intern Med, December 20, 2005; 143(12): 870 - 880. [Abstract] [Full Text] [PDF]

				C. Vaessen, N. Kamar, M. Mehrenberger, C. Mazerolles, C. Mengelle, P. Rischmann, L. Rostaing, and B. Malavaud Severe cytomegalovirus ureteritis in a renal allograft recipient with negative CMV monitoring Nephrol. Dial. Transplant., January 1, 2005; 20(1): 227 - 230. [Full Text] [PDF]

				A. Yango, P. Morrissey, A. Zanabli, J. Beaulieu, D. Shemin, L. Dworkin, A. Monaco, and R. Gohh Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients Nephrol. Dial. Transplant., April 1, 2003; 18(4): 809 - 813. [Abstract] [Full Text] [PDF]

				D. C. BRENNAN Cytomegalovirus in Renal Transplantation J. Am. Soc. Nephrol., April 1, 2001; 12(4): 848 - 855. [Full Text] [PDF]

				Management of herpes virus infections following transplantation J. Antimicrob. Chemother., June 1, 2000; 45(6): 729 - 748. [Full Text] [PDF]

				I. G. Sia and R. Patel New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients Clin. Microbiol. Rev., January 1, 2000; 13(1): 83 - 121. [Abstract] [Full Text] [PDF]

				D. Lowance, H.-H. Neumayer, C. M. Legendre, J.-P. Squifflet, J. Kovarik, P. J. Brennan, D. Norman, R. Mendez, M. R. Keating, G. L. Coggon, et al. Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation N. Engl. J. Med., May 13, 1999; 340(19): 1462 - 1470. [Abstract] [Full Text] [PDF]

				J. Neyts, G. Andrei, and E. De Clercq The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo Antimicrob. Agents Chemother., February 1, 1998; 42(2): 216 - 222. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673